NCT05119738

Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 122 (estimated)
• Sponsor: Pontificia Universidad Catolica de Chile · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and rapidly approved. Novel mRNA vaccines such as the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have reported a stunning \>94% efficacy against COVID-19. However, global access has not been equitable, with many low- and middle-income countries having no vaccine access or access under emergency use mainly to traditional inactivated SARS-CoV2-2 vaccines such as BBIBP-CorV (Sinopharm Beijing), CoronaVac (Sinovac) and BBV152 (Bharat Biotech). Emerging studies have shown that lower concentrations of neutralizing antibodies (Nab) are attained after CoronaVac than after a mRNA-based vaccine in healthy individuals. This difference seems to be more pronounced in immunocompromised patients who are at higher risk of severe COVID-19 and death from COVID-19. As such several countries including United States, Israel and Chile have recommended a third vaccine dose for this vulnerable population. In this observational study we will explore the humoral response to the BNT162b2 vaccine in patients who received two previous doses of the inactivated vaccine Coronavac or two doses of BNT162b2.

Conditions

• Sars-CoV-2 Infection

Interventions

Type	Name	Description
BIOLOGICAL	Three doses of BNT162b2 (observational)	BNT162b2 (COVID 19 mRNA vaccine)
BIOLOGICAL	Two doses of Coronavac and one dose BNT162b2 (observational)	BNT162b2 (COVID 19 mRNA vaccine) Coronavac (COVID 19 inactive vaccine)

Timeline

• Start date: 2021-10-27
• Primary completion: 2022-03-01
• Completion: 2022-06-01
• First posted: 2021-11-15
• Last updated: 2022-02-02

Locations

1 site across 1 country: Chile